Drybench Patent.
ABIRATERONE ACETATE; NIRAPARIB TOSYLATE, NDA 216793
The patents and exclusivities FDA's Orange Book lists for NDA 216793 as captured on 14 October 2026, each date named by its rule and its rows, and any rows of FDA's Paragraph IV list captured on 17 October 2026 that give this NDA's number. Listed protection is a range of dates, never one date.
FDA capture · review pending. Each row is shown as captured from FDA's Orange Book files and Paragraph IV list. Dates are FDA's own; spreadsheet day numbers are shown as dates, and a cell that cannot be read as one date is shown as written and left out of the range. Where FDA lists a *PED row without flags, its flags are read from the base row and marked so. A Paragraph IV row is placed here only by the number in its RLD/NDA cell; nothing is joined by name. How this page reads FDA's files has not been independently reviewed by a regulatory-affairs reviewer.
- Orange Book captured
- 14 October 2026
- Paragraph IV list captured
- 17 October 2026
- Last checked
- 30 October 2026
- Data-branch commit
- dadcab56563716abea6c5e31a5e1970080c778ef
Listed protection is a range of the dates FDA lists, not a forecast of market entry, and not legal, regulatory or investment advice.
Dates as listed in FDA's Orange Book capture of 14 October 2026. This page does not say whether a date has passed; compare it with today's date and FDA's current Orange Book. This page shows only what the capture of 14 October 2026 lists. It does not show patents or exclusivities listed before and since removed.
Listed protection
Listed dates run from 11 Aug 2026 to 30 Sep 2043, each by its own rule; no one date stands for this product.
- Earliest listed date
- 11 Aug 2026NP exclusivityRule R3 · Products 001, 002
Source lines
exclusivity.txt lines 1,788, 1,790
- Latest listed date
- 30 Sep 2043US 12,734,180, use patentRule R1 · Products 001, 002
Source lines
patent.txt lines 18,963, 18,987
- Latest substance patent
- 27 Mar 2038US 11,673,877, substance and product and use patentRule R1 · Products 001, 002
Source lines
patent.txt lines 18,952, 18,976
- Latest listed patent
- 30 Sep 2043US 12,734,180, use patentRule R1 · Products 001, 002
Source lines
patent.txt lines 18,963, 18,987
- Latest exclusivity
- 12 Dec 2028I-980 exclusivityRule R3 · Products 001, 002
Source lines
exclusivity.txt lines 1,787, 1,789
Listed dates of other NDAs in the same years:20262027202820292031203720382043
42 use-code patents, blocking the coded use only
Products
Each product number FDA lists under NDA 216793, as listed. The sections below name products by these numbers.
Product 001 · AKEEGA
- Dosage form; route
- TABLET;
ORAL - Strength
- 500MG;EQ 50MG BASE
- Approval date as listed
- 11 Aug 2023
- Type as listed
- RX
- Applicant as listed
- JANSSEN BIOTECH INC
Product 002 · AKEEGA
- Dosage form; route
- TABLET;
ORAL - Strength
- 500MG;EQ 100MG BASE
- Approval date as listed
- 11 Aug 2023
- Type as listed
- RX
- Applicant as listed
- JANSSEN BIOTECH INC
Listed patents
Every patent the FDA lists for this product, as the application holder submitted it, with its flags. The FDA does not verify listings.
24 entries from 48 rows as listed; rows merge only where every cell shown is the same, each with its product numbers.
US 8,071,579, use patent
patent.txt lines 18,964, 18,988- Expiry as listed
- 12 Aug 2027
- Rule
- R1
- Flags
- use code U-2830
- Product numbers
- 001, 002
US 8,071,579, use patent
patent.txt lines 18,965, 18,989- Expiry as listed
- 12 Aug 2027
- Rule
- R1
- Flags
- use code U-4368
- Product numbers
- 001, 002
US 8,143,241, use patent
patent.txt lines 18,967, 18,991- Expiry as listed
- 12 Aug 2027
- Rule
- R1
- Flags
- use code U-2830
- Product numbers
- 001, 002
US 8,143,241, use patent
patent.txt lines 18,968, 18,992- Expiry as listed
- 12 Aug 2027
- Rule
- R1
- Flags
- use code U-4368
- Product numbers
- 001, 002
US 8,436,185, substance and product patent
patent.txt lines 18,969, 18,993- Expiry as listed
- 24 Apr 2029
- Rule
- R1
- Flags
- substance · product
- Product numbers
- 001, 002
US 8,071,623, substance and product patent
patent.txt lines 18,966, 18,990- Expiry as listed
- 27 Mar 2031
- Rule
- R1
- Flags
- substance · product
- Product numbers
- 001, 002
US 8,859,562, use patent
patent.txt lines 18,970, 18,994- Expiry as listed
- 4 Aug 2031
- Rule
- R1
- Flags
- use code U-2830
- Product numbers
- 001, 002
US 8,859,562, use patent
patent.txt lines 18,971, 18,995- Expiry as listed
- 4 Aug 2031
- Rule
- R1
- Flags
- use code U-4368
- Product numbers
- 001, 002
US 11,207,311, use patent
patent.txt lines 18,949, 18,973- Expiry as listed
- 28 Jul 2037
- Rule
- R1
- Flags
- use code U-2830
- Product numbers
- 001, 002
US 11,207,311, use patent
patent.txt lines 18,950, 18,974- Expiry as listed
- 28 Jul 2037
- Rule
- R1
- Flags
- use code U-4368
- Product numbers
- 001, 002
US 11,986,468, use patent
patent.txt lines 18,953, 18,977- Expiry as listed
- 28 Jul 2037
- Rule
- R1
- Flags
- use code U-2830
- Product numbers
- 001, 002
US 11,986,468, use patent
patent.txt lines 18,954, 18,978- Expiry as listed
- 28 Jul 2037
- Rule
- R1
- Flags
- use code U-4368
- Product numbers
- 001, 002
US 11,986,469, use patent
patent.txt lines 18,955, 18,979- Expiry as listed
- 28 Jul 2037
- Rule
- R1
- Flags
- use code U-2830
- Product numbers
- 001, 002
US 11,986,469, use patent
patent.txt lines 18,956, 18,980- Expiry as listed
- 28 Jul 2037
- Rule
- R1
- Flags
- use code U-4368
- Product numbers
- 001, 002
US 11,986,470, use patent
patent.txt lines 18,957, 18,981- Expiry as listed
- 28 Jul 2037
- Rule
- R1
- Flags
- use code U-4368
- Product numbers
- 001, 002
US 11,992,486, use patent
patent.txt lines 18,958, 18,982- Expiry as listed
- 28 Jul 2037
- Rule
- R1
- Flags
- use code U-2830
- Product numbers
- 001, 002
US 11,992,486, use patent
patent.txt lines 18,959, 18,983- Expiry as listed
- 28 Jul 2037
- Rule
- R1
- Flags
- use code U-4368
- Product numbers
- 001, 002
US 12,383,543, use patent
patent.txt lines 18,960, 18,984- Expiry as listed
- 28 Jul 2037
- Rule
- R1
- Flags
- use code U-2830
- Product numbers
- 001, 002
US 12,383,543, use patent
patent.txt lines 18,961, 18,985- Expiry as listed
- 28 Jul 2037
- Rule
- R1
- Flags
- use code U-4368
- Product numbers
- 001, 002
US 11,091,459, substance and product patent
patent.txt lines 18,948, 18,972- Expiry as listed
- 27 Mar 2038
- Rule
- R1
- Flags
- substance · product
- Product numbers
- 001, 002
US 11,673,877, substance and product and use patent
patent.txt lines 18,951, 18,975- Expiry as listed
- 27 Mar 2038
- Rule
- R1
- Flags
- substance · product · use code U-2830
- Product numbers
- 001, 002
US 11,673,877, substance and product and use patent
patent.txt lines 18,952, 18,976- Expiry as listed
- 27 Mar 2038
- Rule
- R1
- Flags
- substance · product · use code U-4368
- Product numbers
- 001, 002
US 12,734,180, use patent
patent.txt lines 18,962, 18,986- Expiry as listed
- 30 Sep 2043
- Rule
- R1
- Flags
- use code U-4608
- Product numbers
- 001, 002
US 12,734,180, use patent
patent.txt lines 18,963, 18,987- Expiry as listed
- 30 Sep 2043
- Rule
- R1
- Flags
- use code U-4609
- Product numbers
- 001, 002
Listed exclusivities
Each exclusivity FDA lists for NDA 216793, with its code, FDA's definition of the code where the store's code list gives one, and its date as listed.
NP exclusivity
exclusivity.txt lines 1,788, 1,790- Date
- 11 Aug 2026
- Rule
- R3
- Definition
- New product (to be checked against FDA's list)
- Product numbers
- 001, 002
I-980 exclusivity
exclusivity.txt lines 1,787, 1,789- Date
- 12 Dec 2028
- Rule
- R3
- Definition
- New indication (to be checked against FDA's list)
- Product numbers
- 001, 002
Paragraph IV list rows giving NDA 216793
The rows of FDA's Paragraph IV certifications list as captured on 17 October 2026 whose RLD/NDA cell gives NDA 216793, each cell as listed.
Rows with no NDA number this page can match are kept apart on the list page; some may concern this product.
No row of the Paragraph IV list captured on 17 October 2026 gives NDA 216793 in its RLD/NDA cell. This does not mean no certification was submitted or that no application challenges a patent listed here.
Notes from the trace
- R6 tentative approvals: not in the Orange Book data files as captured; the Drugs@FDA join is a later ruling.
Patents vs FDA exclusivityHow to read the Orange Book data filesParagraph IV certificationWhat changed, by week